search
Back to results

Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery

Primary Purpose

Analgesia, Obstetrical, Obstetric Surgical Procedures

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Morphine
Hydromorphone
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Analgesia, Obstetrical focused on measuring Cesarean delivery, Analgesia, Intrathecal opioids

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • American Society of Anesthesiologists (ASA) physical status II-III women presenting for elective cesarean delivery
  • Term gestation (37-42 weeks)
  • Desire to have a spinal anesthesia technique for cesarean delivery

Exclusion Criteria:

  • Any contraindication to the administration of a spinal technique for anesthesia
  • History of intolerance or adverse reaction to opioid medications
  • Chronic pain syndrome or current opioid use >30 oral morphine equivalents/day
  • Allergy or intolerance to acetaminophen, ketorolac, ibuprofen, or oxycodone
  • Current BMI > 50

Sites / Locations

  • Mayo Clinic in Rochester

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Intrathecal hydromorphone

Intrathecal morphine

Arm Description

Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.

Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.

Outcomes

Primary Outcome Measures

NRS Score for Pain (0-10) With Movement 24 Hours After Spinal Administration
Each patient will be interviewed by a member of the study team 24 hours after receiving their spinal anesthetic. Patients will be asked to rate their current level of pain on a Numeric Rating Scale (NRS) of 0 (no pain) to 10 (worst pain imaginable).

Secondary Outcome Measures

Nausea
The number of subjects who experienced and self-reported nausea within the first 24 hours after administration of spinal anesthesia.
Pruritus
The number of subjects who experienced and self-reported pruritus within the first 24 hours after administration of spinal anesthesia.

Full Information

First Posted
May 31, 2016
Last Updated
April 24, 2019
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT02789410
Brief Title
Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery
Official Title
Intrathecal Morphine Versus Intrathecal Hydromorphone for Analgesia Following Cesarean Delivery
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
May 2016 (undefined)
Primary Completion Date
September 2017 (Actual)
Study Completion Date
March 15, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Intrathecal (IT) opioids are commonly administered with local anesthetic during spinal anesthesia for post-Cesarean delivery analgesia. Traditionally, IT morphine has been used but the use of IT hydromorphone is growing. A previous study has shown that the effective dose for postoperative analgesia in 90% patients (ED90) for both IT hydromorphone and IT morphine (NCT02009722). These doses were found to be 75 mcg for hydromorphone and 150 mcg for morphine. The current proposed study would compare the duration of analgesia of IT morphine vs IT hydromorphone after elective cesarean delivery. Additionally, the investigators will compare each drug with respect the incidence of nausea and pruritus.
Detailed Description
Spinal anesthesia is the most common anesthetic technique used for Cesarean delivery in the United States and across the world. Intrathecal opioids are administered with a local anesthetic during spinal anesthesia post-Cesarean delivery analgesia. The effectiveness of intrathecal morphine for post-Cesarean pain control is well established, and the use of intrathecal hydromorphone in this patient population is growing. No prospective studies have been conducted to specifically compare the efficacy of intrathecal morphine versus hydromorphone for post-Cesarean analgesia. After intrathecal administration, opioid drug disposition depends on the lipid solubility of the individual drug. Because of its hydrophilic nature, cerebrospinal fluid (CSF) concentrations of morphine decline more slowly than similar doses of lipophilic drugs. This accounts for more rostral spread, greater dermatomal analgesia, and longer duration of action when compared to highly lipophilic opioids like fentanyl and sufentanil. When used for post-cesarean analgesia, intrathecal morphine has a duration of action between 14-36 hours with wide variation between individual patients. While hydromorphone is similar chemically to morphine, it is more lipid soluble. This decreases its spread within the intrathecal space and enhances its penetration into the dorsal horn of the spinal cord where interactions with opioid receptors occur. These differences between the two medications may influence their duration of action. Theoretically, this would reduce the duration of action of intrathecal hydromorphone when compared with intrathecal morphine. Retrospective studies have shown that the analgesic benefit for intrathecal hydromorphone appears to extend at least 12 hours after cesarean delivery and may extend up to 24 hours. Although effective in reducing pain, intrathecal opioids are associated with side effects including pruritus, nausea, and respiratory depression. A meta-analysis reviewing twenty-eight studies which investigated intrathecal morphine versus placebo demonstrated moderate increases in the incidences of pruritus, nausea and vomiting. In fact the incidence of nausea with IT morphine has been reported to be nearly 33%. The differences in pharmacokinetics between morphine and hydromorphone may also create differences in side effect profiles. Some studies have found that hydromorphone causes less nausea and pruritus than morphine, while others have not. Although opioid-induced respiratory depression is a rare event, studies evaluating intrathecal hydromorphone for post-Cesarean delivery pain have not reported any cases of respiratory depression. In this study, the investigators aim to compare the duration of analgesia of intrathecal morphine vs. hydromorphone for analgesia after cesarean delivery. Secondarily, the investigators will compare the side effects of each drug, including nausea and pruritus. To achieve the goals of this study, it is important to study equipotent doses of these medications. Previous work by the investigators of this study found that the effective dose for postoperative analgesia in 90% of patients (ED90) is 75 micrograms for intrathecal hydromorphone and 150 micrograms for intrathecal morphine. However, it is not known if these two equipotent medication doses provide a similar duration of analgesia. The investigators hypothesize that 150 mcg of intrathecal morphine will result in a longer duration of analgesia when compared to 75 micrograms of intrathecal hydromorphone. Additionally, the investigators hypothesize that there will be more pruritus in the intrathecal hydromorphone group early after surgery, and no difference in side effects at 24 hours after surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Analgesia, Obstetrical, Obstetric Surgical Procedures
Keywords
Cesarean delivery, Analgesia, Intrathecal opioids

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
134 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intrathecal hydromorphone
Arm Type
Active Comparator
Arm Description
Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
Arm Title
Intrathecal morphine
Arm Type
Active Comparator
Arm Description
Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
Intervention Type
Drug
Intervention Name(s)
Morphine
Other Intervention Name(s)
Duramorph
Intervention Description
Morphine is administered as part of spinal anesthesia for post-operative pain relief.
Intervention Type
Drug
Intervention Name(s)
Hydromorphone
Other Intervention Name(s)
Dilaudid
Intervention Description
Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
Primary Outcome Measure Information:
Title
NRS Score for Pain (0-10) With Movement 24 Hours After Spinal Administration
Description
Each patient will be interviewed by a member of the study team 24 hours after receiving their spinal anesthetic. Patients will be asked to rate their current level of pain on a Numeric Rating Scale (NRS) of 0 (no pain) to 10 (worst pain imaginable).
Time Frame
24 hours after administration of spinal anesthesia
Secondary Outcome Measure Information:
Title
Nausea
Description
The number of subjects who experienced and self-reported nausea within the first 24 hours after administration of spinal anesthesia.
Time Frame
24 hours after administration of spinal anesthesia
Title
Pruritus
Description
The number of subjects who experienced and self-reported pruritus within the first 24 hours after administration of spinal anesthesia.
Time Frame
24 hours after administration of spinal anesthesia

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: American Society of Anesthesiologists (ASA) physical status II-III women presenting for elective cesarean delivery Term gestation (37-42 weeks) Desire to have a spinal anesthesia technique for cesarean delivery Exclusion Criteria: Any contraindication to the administration of a spinal technique for anesthesia History of intolerance or adverse reaction to opioid medications Chronic pain syndrome or current opioid use >30 oral morphine equivalents/day Allergy or intolerance to acetaminophen, ketorolac, ibuprofen, or oxycodone Current BMI > 50
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hans P Sviggum
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
16129992
Citation
Bucklin BA, Hawkins JL, Anderson JR, Ullrich FA. Obstetric anesthesia workforce survey: twenty-year update. Anesthesiology. 2005 Sep;103(3):645-53. doi: 10.1097/00000542-200509000-00030. No abstract available.
Results Reference
background
PubMed Identifier
26974022
Citation
Sviggum HP, Arendt KW, Jacob AK, Niesen AD, Johnson RL, Schroeder DR, Tien M, Mantilla CB. Intrathecal Hydromorphone and Morphine for Postcesarean Delivery Analgesia: Determination of the ED90 Using a Sequential Allocation Biased-Coin Method. Anesth Analg. 2016 Sep;123(3):690-7. doi: 10.1213/ANE.0000000000001229.
Results Reference
background
PubMed Identifier
19462494
Citation
Gehling M, Tryba M. Risks and side-effects of intrathecal morphine combined with spinal anaesthesia: a meta-analysis. Anaesthesia. 2009 Jun;64(6):643-51. doi: 10.1111/j.1365-2044.2008.05817.x.
Results Reference
background
PubMed Identifier
9952150
Citation
Palmer CM, Emerson S, Volgoropolous D, Alves D. Dose-response relationship of intrathecal morphine for postcesarean analgesia. Anesthesiology. 1999 Feb;90(2):437-44. doi: 10.1097/00000542-199902000-00018. Erratum In: Anesthesiology 1999 Apr;90(4):1241.
Results Reference
background
PubMed Identifier
12928713
Citation
Terajima K, Onodera H, Kobayashi M, Yamanaka H, Ohno T, Konuma S, Ogawa R. Efficacy of intrathecal morphine for analgesia following elective cesarean section: comparison with previous delivery. J Nippon Med Sch. 2003 Aug;70(4):327-33. doi: 10.1272/jnms.70.327.
Results Reference
background
PubMed Identifier
23965210
Citation
Beatty NC, Arendt KW, Niesen AD, Wittwer ED, Jacob AK. Analgesia after Cesarean delivery: a retrospective comparison of intrathecal hydromorphone and morphine. J Clin Anesth. 2013 Aug;25(5):379-383. doi: 10.1016/j.jclinane.2013.01.014. Epub 2013 Aug 17.
Results Reference
background
PubMed Identifier
23248827
Citation
Rauch E. Intrathecal hydromorphone for postoperative analgesia after cesarean delivery: a retrospective study. AANA J. 2012 Aug;80(4 Suppl):S25-32.
Results Reference
background
PubMed Identifier
23256273
Citation
Rauch E. Intrathecal hydromorphone for cesarean delivery: in search of improved postoperative pain management: a case report. AANA J. 2011 Oct;79(5):427-32.
Results Reference
background
PubMed Identifier
12697596
Citation
Nortcliffe SA, Shah J, Buggy DJ. Prevention of postoperative nausea and vomiting after spinal morphine for Caesarean section: comparison of cyclizine, dexamethasone and placebo. Br J Anaesth. 2003 May;90(5):665-70. doi: 10.1093/bja/aeg120.
Results Reference
background
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery

We'll reach out to this number within 24 hrs